3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Uterine Cervical Neoplasms
20
Papillomavirus Infections
12
Uterine Cervical Dysplasia
9
Condylomata Acuminata
7
Vulvar Neoplasms
4
Anus Neoplasms
4
Vaginal Neoplasms
3
Virus Diseases
1
Persistent Infection
1
Neoplasms
1
Neoplasm Metastasis
1
Inflammatory Bowel Diseases
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Crohn Disease
1
Colitis, Ulcerative
1
Cervical Cancer Screening
1
Acquired Immunodeficiency Syndrome
1
Interventions
pembrolizumab
23
Paclitaxel
14
Cyclophosphamide
13
Carboplatin
12
Specimen Handling
10
Magnetic Resonance Spectroscopy
10
Biopsy
9
fludarabine
8
Nivolumab
7
Leucovorin
7
Gemcitabine
7
Fluorouracil
7
Doxorubicin
7
aldesleukin
6
Oxaliplatin
6
Cisplatin
6
liposomal doxorubicin
5
Topotecan
5
Taxes
5
Irinotecan
5
Interleukin-2
5
olaparib
4
atezolizumab
4
Hyperthermic Intraperitoneal Chemotherapy
4
Drug Therapy
4
seribantumab
3
fludarabine phosphate
3
durvalumab
3
dostarlimab
3
dehydroftorafur
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm Metastasis
×
Papillomavirus Vaccines
×
Gynecologic
×
Clear all
NCT06686043
2024-11-13
HPV-VIM
Baylor College of Medicine
Phase 2
Recruiting
85 enrolled